Au Burkina Faso, les personnes vivant avec le VIH (PvVIH) ont régulièrement recours à des substances naturelles pour traiter certaines infections opportunistes. C’est ainsi que le suc des feuilles fraîches de Mitracarpus scaber Zucc. ex Schult. & Schult. f. (Rubiaceae) et de Senna alata (L.) R
...
oxb. (Fabaceae) sont utilisés comme antimycosiques. En ce qui concerne le zona et les poussées herpétiques, les feuilles fraîches de Phyllanthus amarus Schumach. & Thonn. (Euphorbiaceae), la sève de Mangifera indica L. (Anacardiaceae), le gel de Aloe buettneri Berger (Liliaceae) et la galle de Guiera senegalensis J.F. Gmel. (Combretaceae), sont les drogues végétales les plus utilisées. Des substances naturelles sont également recommandées par les tradipraticiens de santé pour la récupération immunologique et nutritionnelle, le traitement précoce de l’infection à VIH et la réduction des effets secondaires des traitements ARV (antirétroviral). Il s’agit respectivement pour les plus importantes d’entre elles, des feuilles de Moringa oleifera Lam. (Moringaceae), de la pulpe du fruit de Detarium microcarpum Guill. & Perr. (Fabaceae), de la spiruline et du pollen issu de la ruche.
Les substances naturelles pouvant avoir une interaction avec les traitements conventionnels et plus particulièrement avec les médicaments ARV, les plantes contenant des tanins catéchiques, des dérivés 1,8 hydroxyanthracéniques laxatifs et des molécules hépatotropes ou inductrices enzymatiques, sont classées à risque, et leur utilisation par les PvVIH est étroitement surveillée.
more
Le profil pharmaceutique du pays présente des données sur les conditions socioéconomiques existantes et celles de la santé, les ressources, les structures règlementaires, les processus et les résultats relatifs au secteur pharmaceutique au Burkina-Faso. Ce document a pour but de compiler toute
...
s les informations existantes et pertinentes sur le secteur pharmaceutique et de les diffuser auprès du grand public d’une manière accessible.
more
Socioeconomic status is associated with differences in risk factors for cardiovascular disease incidence and outcomes, including mortality. However, it is unclear whether the associations between cardiovascular disease and common measures of socioeconomic status—wealth and education—differ among
...
high-income, middle-income, and low-income countries, and, if so, why these differences exist. We explored the association between education and household wealth and cardiovascular disease and mortality to assess which marker is the stronger predictor of outcomes, and examined whether any differences in cardiovascular disease by socioeconomic status parallel differences in risk factor levels or differences in management.
more
This document is an output of a WHO cross-programme initiative aiming to improve the prevention, diagnosis and management of anaemia and thereby accelerate reduction in its prevalence. It comes at an important time, midway through the era of the Sustainable Development Goals, when progress in reduci
...
ng anaemia has stagnated. This framework is based on the core principles of primary health care: meeting people’s health needs through comprehensive promotive, protective, curative, and rehabilitative care along the life course; systematically addressing the broader determinants of health; and empowering individuals, families, and communities to optimize their health
more
DHS Working Papers No. 86
This Technical Brief focuses on current principles and approaches to Moderate Acute Malnutrition (MAM) management, highlighting key constraints, gaps in knowledge and areas still lacking consensus. It is intended to inform ongoing debates among practitioners, national partners, donors and analysts o
...
n what information and evidence on best practices are currently available, where the gaps are, and priorities for going forward.
more
VOX Sanguinis, 2021:
The coronavirus disease 2019 (COVID-19) affected millions of people worldwide and caused disruptions at the global level including in healthcare provision. Countries of the WHO African region have put in place measures for the COVID-19 pandemic containment that may adversely a
...
ffect blood system activities and subsequently reduce the supply and demand of blood and blood components. This study aims to assess the impact of the COVID-19 pandemic on blood supply and demand in the WHO African Region and propose measures to address the challenges faced by countries.
more
Today, the World Health Organization (WHO) is advancing the global fight against acute malnutrition in children under 5 with the launch of its new guideline on the prevention and management of wasting and nutritional oedema (acute malnutrition). This milestone is a crucial response to the persistent
...
global issue of acute malnutrition, which affects millions of children worldwide.
In 2015, the world committed to achieving the Sustainable Development Goals (SDGs), including the ambitious target of eliminating malnutrition in all of its forms by 2030. However, despite these commitments, the proportion of children with acute malnutrition has persisted at a worrying level, affecting an estimated 45 million children under five worldwide in 2022.
In 2022, approximately 7.3 million children received treatment for severe acute malnutrition (SAM). Although treatment coverage has increased, children with SAM in many of the worst affected countries are still unable to access the full necessary care for them to recover.
The Global Action Plan (GAP) on child wasting recognized the need for updated normative guidance to support governments in the prevention and management of acute malnutrition. WHO answered this call to action and developed a comprehensive guideline that provides evidence-based recommendations and good practice statements and will be followed by guidance and tools for implementation.
more
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov
...
ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more